Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.40 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.32 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1067809 | 1.00 | SPHK1 (0.50) | SPHK1NR1H2HSD11B2BRD4CHRM2 | |
| SCHEMBL1526136 | 1.00 | SPHK1 (0.50) | SPHK1NR1H2HSD11B2BRD4CHRM2 | |
| SCHEMBL15318844 | 0.88 | SPHK1 (0.48) | SPHK1NR1H2HSD11B2BRD4CHRM2 | |
| SCHEMBL1068506 | 0.88 | SPHK1 (0.48) | SPHK1NR1H2HSD11B2BRD4CHRM2 | |
| SCHEMBL30695331 | 0.88 | SPHK1 (0.51) | SPHK1NR1H2HSD11B2BRD4CHRM2 | |
| SCHEMBL1068504 | 0.88 | SPHK1 (0.48) | SPHK1NR1H2HSD11B2BRD4CHRM2 | |
| SCHEMBL20621505 | 0.88 | SPHK1 (0.53) | SPHK1NR1H2HSD11B2BRD4CHRM2 | |
| SCHEMBL6125269 | 0.88 | SPHK1 (0.53) | SPHK1NR1H2HSD11B2BRD4CHRM2 | |
| SCHEMBL26468958 | 0.88 | SPHK1 (0.53) | SPHK1NR1H2HSD11B2BRD4CHRM2 | |
| SCHEMBL13110172 | 0.87 | SPHK1 (0.49) | SPHK1NR1H2HSD11B2BRD4CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122080069-A | Phospholipid compounds and uses thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| EP-4651953-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| EP-4651945-A1 | COMPOSITIONS USEFUL FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| US-12473314-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-20250326773-A1 | MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDER | KYORIN SEIYAKU KK (JP) | 2025-10-23 | — | — | US | disclosed |
| US-20250326772-A1 | MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDER | KYORIN SEIYAKU KK (JP) | 2025-10-23 | — | — | US | disclosed |
| EP-4537828-A2 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-4200301-B1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-02-26 | — | — | EP | disclosed |
| WO-2025034858-A1 | FUSED PYRIDINES FOR THE TREATMENT OF CANCER AND OTHER INDICATIONS | THERAS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| US-20070088002-A1 | Orally available sphingosine 1-phosphate receptor agonists and antagonists | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-04-19 | — | — | US | disclosed |
| EP-1740522-A2 | BISPHENYL COMPOUNDS USEFUL AS VITAMIN D SB 3 /SB RECEPTOR AGONISTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-01-10 | — | — | EP | disclosed |
| US-20060025474-A1 | Bisphenyl compounds useful as vitamin D3 receptor agonists | CHUGAI SEIYAKU KABUSHIKA KAISHA (JP) | 2006-02-02 | — | — | US | disclosed |
| WO-2005087700-A2 | BISPHENYL COMPOUNDS USEFUL AS VITAMIN D3 RECEPTOR AGONISTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-09-22 | — | — | WO | disclosed |
| US-5763436-A | ANTICOAGULANTS | HOFFMANN-LA ROCHE INC. (US) | 1998-06-09 | — | — | US | disclosed |
| US-5595999-A | ANTICOAGULANTS | HOFFMANN-LA ROCHE INC. (US) | 1997-01-21 | — | — | US | disclosed |
| US-5583133-A | ANTICOAGULANTS | HOFFMANN-LA ROCHE INC. (US) | 1996-12-10 | — | — | US | disclosed |
| US-5532232-A | INHIBIT THROMBIN INDUCED PLATELET AGGREGATION; FIBRINOGEN ANTICOAGULANTS IN BLOOD | HOFFMANN-LA ROCHE INC. (US) | 1996-07-02 | — | — | US | disclosed |
| US-5393760-A | Cardiovascular disorders, antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 1995-02-28 | — | — | US | disclosed |
| US-5260307-A | Inhibit thrombin-induced platlet aggregation and clotting of fibrogen in plasma | HOFMANN-LA ROCHE INC. (US) | 1993-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088002-A1 | Orally available sphingosine 1-phosphate receptor agonists and antagonists | S1PR3, S1PR1, S1PR5 | SPHK1 6/4885NR1H2 253/4885HSD11B2 1277/4885 |
| US-20250326772-A1 | MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDER | MRGPRX2, MRGPRX1, MRGPRX4 | SPHK1 755/4885NR1H2 157/4885HSD11B2 480/4885 |
| US-20250326773-A1 | MRGPRX2 ANTAGONISTS, PHARMACEUTICAL COMPOSITION INCLUDING MRGPRX2 ANTAGONIST, AND METHOD OF TREATING MRGPRX2-MEDIATED DISEASE OR DISORDER | MRGPRX2, MRGPRX1, MRGPRX4 | SPHK1 755/4885NR1H2 157/4885HSD11B2 480/4885 |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | CD274, PDCD1LG2, PDCD1 | SPHK1 4476/4885NR1H2 95/4885HSD11B2 1259/4885 |
| US-20060025474-A1 | Bisphenyl compounds useful as vitamin D3 receptor agonists | VDR, CYP2R1, CYP24A1 | SPHK1 2158/4885NR1H2 45/4885HSD11B2 677/4885 |
| US-12473314-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | SPHK1 110/4885NR1H2 260/4885HSD11B2 3417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.